Abstract
While it is now evident that Omicron is rapidly replacing Delta, due to a combination of increased transmissibility and immune escape, it is less clear how the severity of Omicron compares to Delta. In Ontario, we sought to examine hospitalization and death associated with Omicron, as compared to matched cases infected with Delta. We conducted a matched cohort study, considering time to hospitalization or death as the outcome, and analyzed with a Cox proportional hazards model. Cases were matched on age, gender, and onset date, while vaccine doses received and time since vaccination were included as adjustment variables. We identified 6,314 Omicron cases that met eligibility criteria, of which 6,312 could be matched with at least one Delta case (N=8,875) based on age, gender, and onset date. There were 21 (0.3%) hospitalizations and 0 (0%) deaths among matched Omicron cases, compared to 116 (2.2%) hospitalizations and 7 (0.3%) deaths among matched Delta cases. The adjusted risk of hospitalization or death was 54% lower (HR=0.46, 95%CI: 0.27, 0.77) among Omicron cases compared to Delta cases. While severity may be reduced, the absolute number of hospitalizations and impact on the healthcare system could still be significant due to the increased transmissibility of Omicron.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any external funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was reviewed and approved by the research ethics board of Public Health Ontario.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data from this study is not publically available.
